TY - JOUR
T1 - Patients’ perception of vitiligo severity
AU - van Geel, Nanja
AU - Moock, Charlotte
AU - Zuidgeest, Marloes
AU - Uitentuis, Sanne Elisabeth
AU - Wolkerstorfer, Albert
AU - Speeckaert, Reinhart
N1 - Funding Information: We thank all participating patients in this study and the Dutch Society for Vitiligo patients (Vitiligo.nl). The study was approved by the local ethics committees (reference number Ghent: B670201421409; reference number Amsterdam: W15_117#15.00147). EADV grant (EADV Project proposal reference number 2015-030), Leo Foundation grant (Leo Foundation project reference number LF16092) and grant from Incyte Bioscience. The research activities of N. van Geel are supported by the Scientific Research Foundation-Flanders (FWO Senior Clinical Investigator: 1831512N). The research activities of the R. Speeckaert are supported by the Scientific Research Foundation-Flanders (Krediet aan Navorsers: 1504718N and FWO Senior Clinical Investigator: 18B2721N). NvG is a consultant and/or investigator for Pfizer, Laboratoire G?n?vrier, Incyte, Sunpharma. Funding Information: We thank all participating patients in this study and the Dutch Society for Vitiligo patients (Vitiligo.nl). The study was approved by the local ethics committees (reference number Ghent: B670201421409; reference number Amsterdam: W15_117#15.00147). EADV grant (EADV Project proposal reference number 2015-030), Leo Foundation grant (Leo Foundation project reference number LF16092) and grant from Incyte Bioscience. The research activities of N. van Geel are supported by the Scientific Research Foundation-Flanders (FWO Senior Clinical Investigator: 1831512N). The research activities of the R. Speeckaert are supported by the Scientific Research Foundation-Flanders (Krediet aan Navorsers: 1504718N and FWO Senior Clinical Investigator: 18B2721N). NvG is a consultant and/or investigator for Pfizer, Laboratoire Génévrier, Incyte, Sunpharma. Publisher Copyright: © 2021, Medical Journals/Acta D-V. All rights reserved.
PY - 2021
Y1 - 2021
N2 - Identifying which factors contribute to vitiligo severity and determining their individual weight are important in the management of vitiligo. The aim of this study is to investigate the predictive variables concerning vitiligo severity as perceived by the patients. Based on a questionnaire, several factors that may contribute to the Patient Global Assessment (PtGA) of severity were investigated within a Belgian vitiligo population (n = 291). In addition, possible factors influencing vitiligo severity were scored and ranked. The strongest correlations with the PtGA of severity were found for impact, Dermatology Life Quality Index and disease extent. Based on multivariable regression analyses, 64.7% of PtGA of severity could be predicted by subjective and objective variables, while 32% could be explained by objective clinical features only. Patients considered lesion location, extent and disease activity as the most important contributing factors to severity. Vitiligo severity is determined by objective clinical features, but also, for a significant part, by the perceived impact of the disease.
AB - Identifying which factors contribute to vitiligo severity and determining their individual weight are important in the management of vitiligo. The aim of this study is to investigate the predictive variables concerning vitiligo severity as perceived by the patients. Based on a questionnaire, several factors that may contribute to the Patient Global Assessment (PtGA) of severity were investigated within a Belgian vitiligo population (n = 291). In addition, possible factors influencing vitiligo severity were scored and ranked. The strongest correlations with the PtGA of severity were found for impact, Dermatology Life Quality Index and disease extent. Based on multivariable regression analyses, 64.7% of PtGA of severity could be predicted by subjective and objective variables, while 32% could be explained by objective clinical features only. Patients considered lesion location, extent and disease activity as the most important contributing factors to severity. Vitiligo severity is determined by objective clinical features, but also, for a significant part, by the perceived impact of the disease.
KW - Impact
KW - Outcome
KW - Patient-reported outcomes
KW - Quality of life
KW - Severity
KW - Vitiligo
UR - http://www.scopus.com/inward/record.url?scp=85110435557&partnerID=8YFLogxK
U2 - https://doi.org/10.2340/00015555-3823
DO - https://doi.org/10.2340/00015555-3823
M3 - Article
C2 - 33954797
SN - 0001-5555
VL - 101
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
IS - 6
M1 - adv00481
ER -